A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome

Journal of the American College of Cardiology

Volumn 55, Issue 24, 2010, Pages 2727-2735

  Waksman, Ron ^a   Torguson, Rebecca ^a   Kent, Kenneth M ^a   Pichard, Augusto D ^a   Suddath, William O ^a   Satler, Lowell F ^a   Martin, Brenda D ^a   Perlman, Timothy J ^b   Maltais, Jo Ann B ^b   Weissman, Neil J ^a   Fitzgerald, Peter J ^c   Brewer Jr , H Bryan ^a,b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b Lipid Sciences Inc   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

acute coronary syndrome; atheroma volume regression; HDL delipidation

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD AUTOTRANSFUSION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEART CATHETERIZATION; HUMAN; INTRAVASCULAR ULTRASOUND; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SINGLE BLIND PROCEDURE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ACUTE CORONARY SYNDROME; ADULT; AGED; BLOOD COMPONENT TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 77953107241     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.12.067     Document Type: Article

References (33)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1350-1351
3. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
4. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
6. Genest Jr. J.J., Bard J.M., Fruchart J.C., Ordovas J.M., and Schaefer E.J. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb 13 (1993) 1728-1737
7. Barter P., Gotto A.M., LaRosa J.C., et al., Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 57 (2007) 1301-1310
8. Castelli W.P., Anderson K., Wilson P.W., and Levy D. Lipids and risk of coronary heart disease: The Framingham Study. Ann Epidemiol 2 (1992) 23-28
9. Gordon D.J., and Rifkind B.M. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
10. Wolfram R.M., Brewer H.B., Xue Z., et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol 98 (2006) 711-717
11. Badimon J.J., Badimon L., and Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85 (1990) 1234-1241
12. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., and Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353 (1991) 265-267
13. Plump A.S., Scott C.J., and Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 91 (1994) 9607-9611
14. Hoeg J.M., Santamarina-Fojo S., Bérard A.M., et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci U S A 93 (1996) 11448-11453
15. Brown B.G., Stukovsky K.H., and Zhao X.Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 17 (2006) 631-636
16. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
17. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250
18. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary therosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
19. Sacks F.M., Rudel L.L., Conner A., et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 50 (2009) 894-907
20. Nissen S.E. Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am J Cardiol 87 (2001) 15A-20A
21. Mintz G.S., Nissen S.E., Anderson W.D., et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 37 (2001) 1478-1492
22. Franceschini G., Calabresi L., Chiesa G., et al. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 19 (1999) 1257-1262
23. Glomset J.A. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 9 (1968) 155-167
24. Takahashi Y., and Smith J.D. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. Proc Natl Acad Sci U S A 96 (1999) 11358-11363
25. Remaley A.T., Stonik J.A., Demosky S.J., et al. Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. Biochem Biophys Res Commun 280 (2001) 818-823
26. Oram J.F., and Lawn R.M. ABCA1: the gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 42 (2001) 1173-1179
27. Liu L., Bortnick A.E., Nickel M., et al. Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles. J Biol Chem 278 (2003) 42976-42984
28. Castro G.R., and Fielding C.J. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochem 27 (1988) 25-29
29. Williams D.L., Connelly M.A., Temel R.E., et al. Scavenger receptor B1 and cholesterol trafficking. Curr Opin Lipidol 10 (1999) 329-339
30. Malerod L., Juvet L.K., Hanssen-Bauer A., Eskild W., and Berg T. Oxysterol-activated LXRa′/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. Biochem Biophys Res Comm 299 (2002) 916-923
31. Wang N., Lan D., Chen W., Matsuura F., and Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 101 (2004) 9774-9779
32. Kennedy M.A., Barrera G.C., Nakamura K., et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 1 (2005) 121-131
33. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080